Milestone Scientific

MLSS · NYSE American

$0.3381+$0.0051 (+1.53%)TodayMarket closed · Oct 20, 8:00 PM ET

Prev close $0.333

MLSS analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $1.27 (+277.1% upside)

Low: $1.01
Now: $0.3381
High: $1.58

Upgrades and downgrades

The latest rating actions, newest first

MLSS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Benchmark	Nov 20, 2025	Maintains	Speculative Buy	$1.25 → $1.00	59%

The case for and against

Updated Mar 27, 2025

Bull case

Milestone Scientific Inc. is projected to experience a sales growth rate of 20% as the medical segment begins to contribute modestly in 2025 and accelerates further in 2026. This expected increase in revenue is supported by enhanced coverage of the CompuFlo procedure by more Medicare Administrative Contractors (MACs) and a strategic shift towards direct online sales in the dental sector. Additionally, the company has demonstrated significant improvement in profitability, with gross margins rising to 76.1% in the second quarter of 2024, up from 65% in the same quarter the previous year.

Bear case

Milestone Scientific Inc. faces potential financial challenges due to the need for increased investment in inventory and marketing, which may strain working capital and delay profitability. Additionally, a significant percentage of second dental appointments are canceled due to patient apprehension, contributing to lost revenue for dentists and impacting the company's sales. Lastly, adverse economic conditions or shifts in healthcare reimbursement may result in dentists being hesitant to invest in the company’s technology, further suppressing growth prospects.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.